ClinicalTrials.gg
RecruitingNCT07123181Updated Jun 16, 2026

Oregano and Basil Leaves and Coronary Artery Disease

An interventional study of Control (Standard treatment) and Higher polyphenol intake by consumption of oregano and basil in Acute Coronary Syndromes and Unstable Angina (UA), sponsored by Shahid Beheshti University of Medical Sciences. Recruiting at 1 site in Iran. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Shahid Beheshti University of Medical Sciences · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Study summary

The present study will examine the effects of increasing dietary polyphenol intake by consumption of oregano and basil leaves, on plasma inflammatory and lipid factors and total urinary polyphenol levels in patients who have recently had unstable angina.

Read the detailed description

Several epidemiological studies have shown an inverse relationship between polyphenol consumption and the incidence of chronic diseases, including cardiovascular disease. Dietary polyphenols can act as antioxidants, neutralizing free radicals and reactive oxygen species produced during inflammation. This can helps prevent cellular damage and alleviate oxidative stress-related inflammation. In order to increase the intake of dietary polyphenols, the consumption of vegetables and whole grains has been emphasized, along with the average amount of fruit, fungi, and algae. Moreover, it has been reported that a wider diversity of intake of polyphenols and flavonoid-rich foods when consumed together may represent the optimal approach for improving long-term health. Oregano and basil leaves are two aromatic herbs that are frequently utilized as flavorings in culinary preparations. However, in certain culinary traditions, these herbs are also consumed as part of the daily diet in the form of leafy greens. These herbs have been demonstrated to be excellent sources of polyphenols, particularly rosmarinic acid. The ingestion of these herbs has been shown to augment the dietary intake of beneficial phytochemicals and to support overall antioxidant status. . In addition, these herbs contain active compounds with potential capacity to modulate plasma lipid levels in a beneficial manner that can contribute to the protection of cardiovascular health.

Given the high content of polyphenols in basil and oregano leaves and their potential properties in reducing inflammation and modulating lipids, their consumption may help reduce risk factors associated with coronary heart disease, including unstable angina. The present study will examine the effects of increasing dietary polyphenol intake by consumption of oregano and basil leaves, on plasma inflammatory and lipid factors and total urinary polyphenol levels in patients who have recently had unstable angina.

The present study utilizes a randomized controlled clinical trial design. In this study, patients who meet the established eligibility criteria and are referred to Imam Husain hospital will be included in the study sample. Patients will be randomly assigned to one of two study groups: the control group and the herbs group. The study is scheduled to be conducted over the course of two months. The control group will receive standard medical treatment and general dietary advice, including recommendations to reduce salt, fat, and simple sugar intake. In the herbs group, in addition to the aforementioned recommendations, patients will consume 4-5 grams of dried basil leaves and 4-5 grams of oregano leaves per day. All patients will avoid taking any over-the-counter herbal medications or dietary supplements during the study.

02

Conditions studied

  • Acute Coronary Syndromes
  • Unstable Angina (UA)
03

In context

Acute Coronary Syndrome

1,488 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

This study's planned enrollment of 70 is below the median of 200 across 865 interventional studies indexed under Acute Coronary Syndrome.

Browse Acute Coronary Syndrome studies →

Lead sponsor

Shahid Beheshti University of Medical Sciences is the lead sponsor of 229 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with unstable angina

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with STEMI
  • Patients undergoing coronary artery bypass grafting
  • Liver cirrhosis and advanced chronic kidney disease (CKD 5)
  • Having known inflammatory and diseases, such as inflammatory bowel disease (IBD) and rheumatoid arthritis, or taking medications
  • Pregnancy or breastfeeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Other
    Control

    Standard medical treatment

    Other: Control (Standard treatment)

  • Experimental
    Higher polyphenol intake by consumption of oregano and basil

    Daily consumption of oregano and basil leaves along with standard medical treatment

    Other: Higher polyphenol intake by consumption of oregano and basil

Interventions

  • OtherControl (Standard treatment)

    Patients receive standard medical treatment.

  • OtherHigher polyphenol intake by consumption of oregano and basil

    Patients consume 4-5 grams of dried oregano and 4-5 grams of dried basil leaves daily for two months in addition to their usual medical treatment.

06

What researchers measure

Primary outcomes

  1. Plasma inflammatory biomarkers

    Plasma c-reactive protein, Interleukin-6, RANTES (CCL5)

    Time frame: At the beginning of the study and two months later

  2. Plasma lipids

    Plasma concentrations of triglyceride, cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol

    Time frame: At the beginning of the study and two months later

Secondary outcomes

  1. Plasma malondialdehyde

    Plasma concentrations of malondialdehyde

    Time frame: At the beginning of the study and two months later

  2. Urinary total polyphenols

    Levels total polyphenols in spot urine sample measured by Folin-Ciocalteu method

    Time frame: At the beginning of the study and two months later

  3. Plasma PCSK9 and PAI-1 levels

    plasma concentrations of proprotein convertase subtilisin/kexin type 9 (PCSK9) and plasminogen activator inhibitor 1 (PAI-1)

    Time frame: At the beginning of the study and two months later

07

Study locations

1 of 1 sites recruiting
  • Imam Husain hospital
    Tehran, Tehran Province, Iran
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07123181
Responsible party
Javad Nasrollahzadeh (Associate Professor, Shahid Beheshti University of Medical Sciences) — Principal investigator
First posted
Aug 14, 2025
Start date
Sep 1, 2025
Primary completion
Sep 28, 2026 (estimated)
Completion
Oct 22, 2026 (estimated)
Last update
Jun 16, 2026

Study contacts

Behnaz Pourrajab
Contact
behnazpourrajab@gmail.com
+989380237111

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion